Table 2.

Pharmacokinetic properties of meropenem and vaborbactam. Mean values reported

Populationa		Cmax (mg/L)	CL (L/h)	AUCb (mg·h/L)	t½ (h)
Healthy adultsc	MEM	43.4	15.1	414	1.22
	VAB	55.6	10.9	588	1.68
Patientsc	MEM	57.3	10.5	650	2.30
	VAB	71.3	7.95	835	2.25

AUC area under the concentration–time curve, CL plasma clearance, C_max peak observed concentration, MEM meropenem, t_½ elimination half-life, VAB vaborbactam

^aEight healthy adults [17] and 295 patients (including 35 with impaired renal function) [49] received approved dosages (Sect. 6)

^bAUC_{24 h} (healthy adults) and AUC_{24 h} at steady state (patients)

^cMultiple-dose (7 days) pharmacokinetics (healthy adults) [17] and population pharmacokinetics (patients) [17, 49]